Idera Pharmaceuticals, Inc has announced some top-line results from a randomized, controlled Phase II clinical trial of IMO-2055, the company's investigational cancer drug candidate. IMO-2055 targets Toll-like Receptor 9. Idera was testing it in combination with cetuximab in second-line cetuximab-naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have previously progressed on chemotherapy.
According to the announcement, the study did not meet its primary endpoint of improved progression-free survival following treatment with IMO-2055 plus cetuximab compared to treatment with cetuximab alone.
The median progression-free survival based on investigator assessments was 2.9 months in both arms; based on independent radiology review, it was 1.9 months in the cetuximab arm and 1.5 months in the combination arm.
"We are disappointed with the results of this trial, considering the favorable results reported earlier this year from a single-arm Phase Ib study of IMO-2055 in combination with Tarceva and Avastin in patients with non-small cell lung cancer as well as the safety profile of IMO-2055 in combination with targeted anti-cancer agents that has been observed in multiple clinical trials," said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. "We believe that IMO-2055 may have clinical and commercial potential for certain cancer indications and plan to seek to advance IMO-2055 through collaborations with third parties."
Source: MarketWatch
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
